Cardinal Health shares recently reached their highest level in the past year following a series of positive research notes. Wells Fargo boosted its outlook on the stock, while UBS, Citigroup, Deutsche Bank, TD Cowen and Mizuho all raised their assessments over the past quarter. Fourteen firms now rate the shares a buy and two maintain holds, resulting in a consensus view of Moderate Buy from the analyst community.

In the latest quarter Cardinal Health reported adjusted EPS of 2.55, topping the consensus forecast of 2.22 by 15%. Revenue came in at 64.01 billion, 7.8% above the 59.41 billion estimate, and represented a 22.4% year-over-year increase. The company posted a net margin of 0.68% and carried a negative return on equity of 84.4%, reflecting elevated working capital requirements in its distribution business.

The company’s market capitalization stands at 50.7 billion, supported by a price-to-earnings ratio of 32.2 and a price/earnings-to-growth ratio of 1.52. With a beta of 0.65, the stock has shown lower volatility than the broader market. Technical momentum remains strong, as the 50-day moving average has climbed above the 200-day trend for the first time in over a year.

Cardinal Health recently declared a quarterly dividend of 0.5107 per share, annualized at 2.04 and yielding 1.0% based on current levels, with a payout ratio of roughly 31%. Management reiterated full-year EPS guidance in a range of 9.65 to 9.85, while the Street consensus sits at 7.95, indicating potential upside if operating momentum persists.